VIALE-T, a Phase 3 venetoclax plus azacitidine maintenance trial after transplant in AML, ended on strategic grounds

What was tried

AbbVie ran VIALE-T (NCT04161885), a randomized, open-label Phase 3 study of venetoclax in combination with azacitidine versus best supportive care as maintenance therapy after allogeneic stem cell transplantation in acute myeloid leukemia (ClinicalTrials.gov, NCT04161885). The study had two parts: Part 1 confirmed the dose by measuring dose-limiting toxicities, and Part 2 randomized patients with overall survival as the primary endpoint (ClinicalTrials.gov, NCT04161885). The comparator was best supportive care without AML-directed therapy (ClinicalTrials.gov, NCT04161885). Actual enrollment reached 465 participants, and the primary completion date was recorded as 2025-09-23 (ClinicalTrials.gov, NCT04161885). The study was terminated with the posted reason "Strategic considerations" (ClinicalTrials.gov, NCT04161885).

The biological hypothesis

Venetoclax (CHEMBL3137309, also known as ABT-199) is an oral small-molecule inhibitor of the apoptosis regulator BCL2 (ChEMBL v34). BCL2 sequesters pro-apoptotic effectors, and its inhibition lowers the threshold for mitochondrial apoptosis in leukemic cells (Cell Death and Disease, 2024). The frontline combination of venetoclax and azacitidine is approved for AML and improved survival in unfit patients (Blood, DiNardo et al., 2019). VIALE-T tested a separate hypothesis: that the same regimen, given as maintenance after allogeneic transplant, would extend overall survival relative to observation by suppressing measurable residual disease and delaying relapse. The rationale rests on the idea that BCL2 dependence persists in leukemic stem cells that survive conditioning, and that combinatorial BCL2 family expression in those cells predicts response to venetoclax-based therapy (Cancer Discovery, 2023).

What actually happened

AbbVie stopped the study at full accrual of 465 patients, with the primary completion milestone reached, citing strategic considerations rather than a safety or efficacy finding (ClinicalTrials.gov, NCT04161885). No overall survival result has been released. The pharmacology of the regimen is well characterized. Venetoclax carried 24,069 reports in openFDA FAERS, of which 23,276 were serious and 5,609 listed a death outcome, with top terms dominated by cytopenias: neutropenia (2,580), febrile neutropenia (2,332), myelosuppression (1,910), thrombocytopenia (1,703), and anaemia (1,411) (openFDA FAERS, queried 2026-06-05). In Open Targets, BCL2 carried a strong overall association with AML of 0.5052, built from clinical evidence (0.677), literature (0.967), somatic mutation (0.456), and affected pathway (0.252), with a genetic association datatype of 0 (Open Targets Platform, BCL2 ENSG00000171791, EFO_0000222). BCL2 is a crowded target, with four mechanism-annotated modulators in ChEMBL, including navitoclax, venetoclax, and lisaftoclax (ChEMBL v34).

Failure mechanism, best guess

This termination was strategic, not mechanistic. BCL2 inhibition works in AML, and venetoclax plus azacitidine is an established frontline regimen, so the closure says nothing against the target. The vulnerability sits in the maintenance setting and its endpoint. Overall survival after transplant is a slow, heavily confounded endpoint, because allogeneic transplant is curative-intent and relapsed patients receive salvage that dilutes any maintenance signal. The tolerability profile compounds the problem. Venetoclax-driven myelosuppression, the dominant FAERS signal, is a real tax in a cytopenic post-transplant population where prolonged neutropenia and thrombocytopenia raise infection and bleeding risk (openFDA FAERS, queried 2026-06-05). A maintenance regimen that adds cytopenias to recovering marrow must clear a high survival bar to justify the burden, and a sponsor facing a long readout against that bar can rationally redeploy. Resistance biology adds a further hedge, since monocytic subclones and shifting BCL2 family dependence drive venetoclax escape and would erode a maintenance effect over time (Cancer Discovery, 2020).

How to prevent this next time

Two quantitative tools would have improved the odds that a 465-patient maintenance trial returned a decision rather than a strategic exit.

First, a historical base-rate adjustment with measurable residual disease enrichment. In the 2011 to 2020 record, the likelihood of approval from Phase 1 was 7.9 percent overall, but it reached 25.9 percent for programs using selection biomarkers versus 8.4 percent without (Clinical Development Success Rates 2011-2020, BIO, Informa Pharma Intelligence, QLS Advisors). A maintenance trial that enriches for patients who are measurable-residual-disease positive after transplant concentrates the population with the most to gain and shortens the path to a survival difference, rather than diluting effect across patients already in deep remission.

Second, a Bayesian predictive-probability framework gating the overall survival interim. The predictive probability of success integrates the probability of a positive final result over the posterior for the treatment effect given interim data.

PP(success)=∫θ​P(final success∣θ,interim data)⋅π(θ∣interim data)dθ

A prespecified predictive-probability boundary, with a prior that accounts for salvage confounding and the slow maturation of post-transplant survival, would have set an explicit point at which continued investment was or was not justified, converting a strategic judgment into a numeric stopping rule.

The single highest leverage change would have been to enrich the maintenance population for measurable residual disease positivity after transplant and gate the overall survival interim on a prespecified Bayesian predictive probability rather than running an all-comers survival design against best supportive care.

What this means for similar programs

Maintenance trials after curative-intent transplant are among the hardest survival bets in oncology, because the comparator is already strong and the endpoint matures slowly under salvage. A target that works in active disease does not automatically earn a maintenance indication, and the tolerability profile that is acceptable during induction can become disqualifying during recovery. Programs in this setting should enrich for residual-disease-positive patients, consider relapse-free survival or molecular endpoints as primary, and price the myelosuppression burden into the design before committing to a large overall survival comparison. The BCL2 record shows that a validated mechanism can still produce an uninformative trial when the clinical question and endpoint are mismatched to the setting.

Open questions

What overall survival or relapse-free survival signal, if any, did VIALE-T show before closure, and will AbbVie publish it? Did venetoclax-driven cytopenias limit maintenance dosing or compliance after transplant? Would a measurable-residual-disease-positive subgroup have separated from best supportive care? How much did the difficulty of showing survival benefit in maintenance, versus broader portfolio strategy, drive the decision to stop?

Sources

1. • ClinicalTrials.gov, NCT04161885 (VIALE-T design, two parts, overall survival primary endpoint, best supportive care comparator, enrollment 465, termination reason, primary completion 2025-09-23). - Open Targets Platform: BCL2 (ENSG00000171791) association with acute myeloid leukemia (EFO_0000222) overall 0.5052, clinical 0.677, literature 0.967, somatic mutation 0.456, affected pathway 0.252, genetic association 0. - openFDA FAERS, queried 2026-06-05 (venetoclax: 24,069 reports, 23,276 serious, 5,609 with a death outcome; neutropenia 2,580, febrile neutropenia 2,332, myelosuppression 1,910, thrombocytopenia 1,703, anaemia 1,411). - ChEMBL v34: venetoclax CHEMBL3137309, BCL2 inhibitor, with four mechanism-annotated BCL2 modulators on record. - DiNardo et al., Venetoclax combined with decitabine or azacitidine in treatment-naive elderly patients with AML, Blood, 2019,- Pei et al., Monocytic subclones confer resistance to venetoclax-based therapy in AML, Cancer Discovery, 2020,- Combinatorial BCL2 family expression in AML stem cells predicts clinical response, Cancer Discovery, 2023,- Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia, Cell Death and Disease, 2024,- Clinical Development Success Rates and Contributing Factors 2011-2020, BIO, Informa Pharma Intelligence, QLS Advisors (Phase 1 likelihood of approval 7.9 percent; 25.9 percent with selection biomarkers versus 8.4 percent without). Available from: https://clinicaltrials.gov/study/NCT04161885.